Ryo Otsuka - Publications

T-cell Progenitor-derived Dendritic Cells Contribute to the Repertoire Selection and Immunological Tolerance.

Journal: Transplantation

Published: July 10, 2026

The emerging emetogenicity of trifluridine/tipiracil (TAS‑102) from patient self-reporting: a multicenter, prospective, observational study.

Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

Published: December 22, 2023

Tumor cell-induced macrophage senescence plays a pivotal role in tumor initiation followed by stable growth in immunocompetent condition.

Journal: Journal for immunotherapy of cancer

Published: October 06, 2023

A mechanism of IL-34-induced resistance against cytotoxic anti-cancer therapies such as radiation by X-ray and chemotherapy by Oxaliplatin.

Journal: Oncoimmunology

Published: August 03, 2023

Induced pluripotent stem cell-derived hematopoietic stem and progenitor cells induce mixed chimerism and donor-specific allograft tolerance.

Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Published: November 09, 2022

Induction of allograft tolerance by adoptive transfer of donor B cells: an immune regulatory strategy for transplantation using MHC-matched iPS cells.

Journal: International immunology

Published: September 13, 2022

Development of a colorimetric assay for quantification of favipiravir in human serum using ferrihydrite.

Journal: Talanta

Published: July 30, 2022

Interleukin-34 cancels anti-tumor immunity by PARP inhibitor.

Journal: Journal of gynecologic oncology

Published: June 23, 2022

A Case of Resection of Para-Aortic Lymph Node Recurrence following Rectal Cancer Surgery

Journal: Gan to kagaku ryoho. Cancer & chemotherapy

Published: January 19, 2022

Two Cases of Chemotherapy after Self-Expandable Metallic Stent Placement for Obstructive Sigmoid Cancer with Unresectable Liver Metastasis

Journal: Gan to kagaku ryoho. Cancer & chemotherapy

Published: January 19, 2022

Erratum: Interleukin-34 Limits the Therapeutic Effects of Immune Checkpoint Blockade.

Journal: iScience

Published: January 14, 2022

Tumor-derived interleukin-34 creates an immunosuppressive and chemoresistant tumor microenvironment by modulating myeloid-derived suppressor cells in triple-negative breast cancer.

Journal: Cancer immunology, immunotherapy : CII

Published: January 12, 2022